

(2) 228 करोड़ रुपये की अनुमानित लागत पर संयंत्र का पुनरुद्धार ।

(ख) और (ग) एफ० सी० आई० ने जिसे स्वास्थ्य सर्वेक्षण रिपोर्ट के संदर्भ में अपने बोर्ड की सिफारिशें भेजने को कहा गया था, वर्तमान स्थल पर 837 करोड़ रुपये की अनुमानित लागत पर 900 टन प्रतिदिन अमोनिया और 1500 टन प्रतिदिन यूरिया की क्षमता वाले एक नये नेकथा पर आधारित संयंत्र स्थापित करने को वरीयता दी है। सरकार इस मामले में शीघ्र निर्णय लेने के लिये सभी संभव उपाय करेगी।

Reduction of custom duty on Ceftazidime

3090. SHRI ABDUL SAMAD SIDDIQUI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that the customs duty on Ceftazidime was reduced in July, 1991 but the company did not pass on the benefit of duty reduction by selling indigenously produced formulations at a lower price;

(b) whether it is a fact that the imports of this drug are over-invoiced and after customs duty reduction of bulk drug, formulations prices were jacked up instead of being reduced;

(c) what are the details in this regard and the reasons for reducing customs duty without having cost benefit analysis; and

(d) what steps have been taken to set up a Cell to examine duty rationalisation proposals in his Ministry before duty concessions are granted to ensure that the benefit is passed on to the public?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) The custom duty on bulk drug 'Ceftazidime' was reduced in July, 91. However, the actual import at 0% duty took place only in November, 1991 after necessary amendment in the notification. Ceftazidime in-

jection in the finished form were being imported at 0% custom duty and only after withdrawing custom duty on bulk drug Ceftazidime, the manufacture of Ceftazidime Injection has been started in the country. On import of injection in finished form, admissible margin is 50% only, whereas on indigenously manufactured injection, from imported bulk drug, there is no such restriction. To check whether the benefit of custom duty has been passed on to the consumer, the data submitted by the company is under examination. Regarding overinvoicing of the bulk drug, there is no information with the Government. The custom duty on bulk drug was reduced with a view to encourage indigenous production of formulations instead of importing them and to save foreign exchange.

(d) There is no proposal to set up a separate cell to examine duty rationalisation proposals. Strengthening/reorganising the present administrative arrangement for monitoring the impact of custom duty concessions is under examination.

Returns in form 2-A

3091. SHRIMATI KAILASHPATI:
SHRI RAJNI RANJAN SAHU:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 380 given in the Rajya Sabha on the 30th April, 1992 and state:

(a) whether it is a fact that during 1991-92 only returns in Form 2-A were received in respect of 50 packs;

(b) if so, what are the names of companies which had submitted Form 2-A, names of products and details of packs and what was the extent of price increase for which details were received;

(c) whether it is also a fact that companies went on increasing the prices but did not submit the details;

(d) if so, the details of such instances which came to the notice of Government; and

(e) what steps are being taken to probe into the matter?